ASX:TLXBiotechs
A Look At Telix Pharmaceuticals’ Valuation After ProstACT Global Phase 3 TLX591-Tx Milestone
Telix Pharmaceuticals (ASX:TLX) is back in focus after announcing that Part 1 of its ProstACT Global Phase 3 trial for TLX591-Tx met key safety and tolerability endpoints, clearing the way for the study's expansion.
See our latest analysis for Telix Pharmaceuticals.
The ProstACT Global update comes after a strong 30 day share price return of 24.34% and a 7 day share price return of 5.02%. However, the 1 year total shareholder return shows a decline of 58.55% and the year to date share price...